recifercept

Recifercept is a soluble recombinant protein therapy based on the extracellular domain of the human fibroblast growth factor receptor 3 (FGFR3). It was developed as a decoy receptor to bind and sequester FGFR ligands, thereby reducing aberrant FGFR3 signaling caused by gain-of-function mutations in achondroplasia. By acting as a ligand trap for FGF isoforms relevant to bone growth, recifercept aimed to normalize overactive FGFR3 signaling at the chondrocyte level and promote normal bone development. The drug was originally developed by Therachon and later acquired by Pfizer. Clinical development for achondroplasia was discontinued after phase II trials failed to meet efficacy endpoints[1][4][5][6].

Other names

recombinant human fibroblast growth factor receptor 3soluble recombinant human fibroblast growth factor receptor 3Fibroblast growth factor receptor 3 (recombinant human soluble isoform ta-46)Human fibroblast growth factor receptor 3 (fgfr-3, cd333) (1-336)-(401–413) fragment (1–349) (soluble isoform (337–400>del, 414–784>del)-sfgfr3), produced in chinese hamster ovary cells, glycoform alfa